Pharvaris Announces Pricing of Upsized Initial Public Offering
February 04, 2021 20:08 ET | Source: Pharvaris N.V. Pharvaris N.V. CH Leiden, NETHERLANDS
ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwritin
Terns Pharmaceuticals, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
FOSTER CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share, for gross proceeds of $127.5 million, before the underwriting discounts and commissions. All of the shares of common stock are being offered by Terns. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Terns’ comm
· Value of Malin s stake in Immunocore is approximately €51 million · Malin retains an approximate 6% stake in Immunocore following the IPO Dublin-Ireland, 5 February 2021 : Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies, today notes that its investee company, Immunocore, has announced the pricing of its initial public offering (IPO) of 9.9 million American Depositary Shares (ADSs) representing 9.9 million ordinary shares at an initial public offering price of $26.00 per ADS for total gross proceeds of approximately $258 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market today (5 February 2021) under the ticker symbol IMCR . In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional
Immunocore Prices NASDAQ IPO The Company (LSE: SUPP) is pleased to announce that its portfolio company Immunocore Holdings plc ( Immunocore ) has announced the pricing of its initial public offering ( IPO ) of 9,935,896 American Depositary Shares ( ADSs ) representing 9,935,896 ordinary shares at an IPO price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market ( NASDAQ ) on February 5, 2021 under the ticker symbol IMCR. In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions.